20.1 C
New York

Tag: chinese

Bitcoin Options Expire

The bitcoin and ethereum options on Deribit, one of the largest crypto derivatives exchange, expired earlier today. This month saw the largest open interest in...

Top News

SEMK (2250.HK) Announces 2021 Adjusted Net Profit Increases by Nearly 30% to HK$77 million, Becomes the Largest Domestic Character IP Company In China

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

HONG KONG, Mar 30, 2022 - (ACN Newswire) - SEMK Holdings International Limited ("SEMK", together with its subsidiaries, the "Group", stock code: 2250.HK), the largest domestic character Intellectual Property (IP) company* engaged in the provision of licensing services, design consultation services and retail of licensed brand products of its self-created B.Duck family characters, announced today the first annual results after its listing on the Main Board of The Stock Exchange of Hong Kong Limited on 17 January 2022.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
Mr. Eddie Hui, Chairman and Chief Executive Officer of SEMK.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
Together with its licensee, MADworld, SEMK launched its first drop of B. Duck NFT - 4,000 unique and original design 3D B.Duck NFTs as collectibles and potential future gaming celebrities.

Despite the unprecedented challenges due to the COVID-19 pandemic (the "Pandemic"), SEMK's business remains resilient. The Group's total revenue for the year ended 31 December 2021 ("FY2021" or the "Year") was approximately HK$290.0 million (FY2020: HK$233.5 million), representing a year-on-year growth of 24.2%. Excluding listing-expenses, the adjusted net profit for the Year was HK$77.3 million (FY2020: HK$59.8 million), representing a significant increase of 29.1% from the previous year.

The Board has resolved to declare a final dividend of HK$4.8 cents per ordinary share issued for the year ended 31 December 2021.

Mr. Eddie Hui, Chairman and Chief Executive Officer of SEMK, said, "It is an honor for me, for the first time as Chairman of SEMK, to relate to you our first annual results after listing. I am thrilled to announce that SEMK has become the largest domestic character IP company and ranked the fourth among all character IP companies in China, in terms of character licensing revenue in 2021*. It is our mission to be one of the pioneer Chinese character IP to expand in overseas so that can bring happiness and "Playful" lifestyle worldwide and empower soft power in Chinese cultural style. Indeed, the global licensing market is dominated by American and Japanese IPs, more than 60% of global retail sales of licensed goods attributable to North America. China only occupied less than 4% of global retail value of licensed products in 2021, which is not in same pace of global GDP sharing for China, this implies that the licensing market in China is in a very high growth potential. Our historical pace of growth is much faster than the overall growth rate of licensing market in China. Among other top 10 largest licensors in China, B.Duck is the youngest one and has demonstrated its high growth track records in the past years.

The listing of SEMK on the Main Board of the Hong Kong Stock Exchange in early 2022 is undoubtedly an important milestone for us. Looking forward, we will continue to adhere to our product-oriented development strategy, draw on our strong design capabilities and extensive licensees' network to bring more high-quality products to our fans."

Resilient Business Performance
The Group are principally engaged in two major businesses - character licensing business, as well as e-commerce and other business.

Character Licensing Business
The Group's character licensing business can be broadly divided into five service types, namely (i) merchandise licensing; (ii) location-based entertainment ("LBE") licensing; (iii) content and media licensing; (iv) promotion licensing; and (v) design consultation, which are interrelated and complementary to each other, with each of them being provided on a single, multi-service or integrated basis.

The Group's revenue from character licensing business increased by 69.9% to HK$166.6 million during the Year (FY2020: HK$98.0 million), mainly driven by the increase in excess royalties charged from the Group's licencees as a result of their increased sales of goods or services featuring the Group's IP characters. This segment accounted for 57.4% of the Group's total revenue in FY2021. The number of licencees (exclusive of licensing agents) the Group had increased to 385 as at the end of FY2021 (FY2020: 315).

E-commerce and Other Business
The Group' s e-commerce and other business mainly involve the sale of B.Duck family characters-featured products on e-commerce platforms of third parties and through offline sales channels. Seeing the potential synergies to be generated from the character licensing business, the Group began to explore the possibility of designing and selling its own products on e-commerce platforms. In 2015, SEMK launched its first online flagship store on Tmall, a well-known business to customer online shopping platform in China.

Following the success in the opening of such flagship store, the Group subsequently expanded onto other e-commerce platforms, such as JD.com, VIP.com and HKTVmall, to offer its products and allow customers to pay online with products directly shipped to the customers. During the Year, revenue from e-commerce and other business was approximately HK$123.4 million.

Launch of B. Duck NFTs and MOU with MADworld
With robust design capabilities and creativity, over the decades, the Group was able to ride on its self-create characters to launch various kind of licensed products in order to cope with changing consumption habits of B.Duck's fans. Recently, SEMK deployed a globalized business blueprint with an NFT "Non-fungible token" market. Joining hands with MADworld, the launch of B.Duck NFTs was a three-part series. The first drop, which was already launched, included 4,000 unique and original design 3D B.Duck NFTs as collectibles and potential future gaming celebrities. It was well received by the market and was sold out in 5 hours during the public session.

To facilitate strategic moves in this field in the future, SEMK has also entered into a memorandum of understanding (the "MOU") with MADworld Advisory Limited ("MADworld"), which specializes in development of licensed or licensable IPs into NFTs and other digital creatives, and marketing and offering to sell the same on platforms to be developed and/or accessed by such company. Pursuant to the MOU, SEMK and MADworld shall within two (2) months from the date of the MOU, enter into a joint venture agreement to establish a joint venture entity intended to be principally engaged in, amongst others, development of artworks and IPs owned by the Group into NFTs

Mr. Eddie Hui, Chairman and Chief Executive Officer of SEMK, concluded, "2021 was a peculiar year for us. Against the backdrop of the pandemic, thanks to the robust commitment of our team in delivering the strategic plans, we managed to sustain a resilient performance albeit the market challenges. The opportunities presented by the pandemic prompted us to make sufficient progress in online commercial operations, product flexibility, and B.Duck community online and offline digitalization integration.

Looking forward, through our strong fan base and coverage on social media-and e-commerce platforms, we will continue to accelerate the development of our product design capabilities in different territory, so as to expand to different variety licensing categories, including but not limited to LBE and digital assets projects. We will also proactively look for opportunities of strategic partnerships, alliances and acquisitions to facilitate sustainable business development."

About SEMK Holdings International Limited
SEMK Holdings International Limited (stock code: 2250.HK) is the largest domestic character IP company engaged in the provision of licensing services, design consultation services and retail of brand products of its self-created B.Duck family characters.

With strong in-house artistic design capabilities, SEMK has developed and nurtured a proprietary portfolio of approximately 26 self-created characters created under the motto of "Be Playful". As at 31 December 2021, B.Duck family characters had recorded in aggregate more than 10.5 million subscriptions or follows by B.Duck fans on various e-commerce platforms and social networking platforms, with in aggregate, over 740 million views of various types of content in relation to the elements of B.Duck family characters along with our "Be playful" motto.

Media Enquiries:
Strategic Financial Relations Limited
Heidi So Tel: (852) 2864 4826 Email: heidi.so@sprg.com.hk
Rachel Ko Tel: (852) 2114 2370 Email: rachel.ko@sprg.com.hk
Ivy Chan Tel: (852) 2864 4890 Email: ivy.chan@sprg.com.hk
Website: www.sprg.com.hk


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSEMK Holdings International Limited ("SEMK", together with its subsidiaries, the "Group", stock code: 2250.HK), the largest domestic character Intellectual Property (IP) company* engaged in the provision of licensing services

Dynasty Fine Wines 2021 Revenue Rises Notably by 28% to HKD306 Million Due to Successful “5+4+N” Product Strategy

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

HONG KONG, Mar 29, 2022 - (ACN Newswire) - Dynasty Fine Wines Group Limited ("Dynasty" or "the Group") (Stock Code: 828), a premier grape winemaker in China, today announced its audited annual results for the year ended 31 December 2021. Revenue in 2021 increased by 28% year-on-year to HK$306 million. Gross profit rose by 103% year-on-year to HK$121.9 million. Gross profit margin increased significantly from 25% in 2020 to 40% in 2021. Profit attributable to owners of the Company was HK$32.8 million in 2021, a decrease when compared with HK$116.4 million in 2020. The decline was due to a net gain (after tax) of HK$183.7 million from a disposal, which was a one-off transaction, recorded in 2020. If the net gain of the one-off disposal in 2020 was excluded, profit attributable to owners of the Company would have increased significantly in 2021 versus the preceding year.

In 2021, the revenue of wine products grew, mainly due to a marked increase in sales volume of products, especially middle to high-end wine products, after optimization of the Group's product mix, as well as the increase in market price of certain upgraded and custom-made products during the year. In the second half of 2021, the occurrences of flooding and heavy rain and sporadic COVID-19 cases in certain regions of China adversely affected consumer sentiment. Consequently, the Group's revenue growth for the full 2021 financial year slowed relative to the first half year.

The total number of bottles of wine sold in 2021 was approximately 11.9 million, an increase of 20% as compared with 9.9 million bottles in 2020. Red wines continued to be the Group's primary revenue contributor, accounting for approximately 51% of the Group's revenue for the year (2020: 65%). White wine sales became the growth driver of the Group, which surged by approximately 60% year-on-year and accounted for 40% of the Group' revenue. In 2021, the gross margin of red wine products and white wine products were 37% and 47%, respectively (2020: 24% and 31%, respectively).

The Group produced a wide range of more than 100 wine products under the "Dynasty" brand. This has enabled it to meet the demands and preferences of different consumer groups, mainly in the mass segment of the Chinese wine market. During the year, the Group launched a new premium product, Dynasty Chinese Zodiac Commemorative Dry Red Wine, for the Xin Chou Year of the Ox, integrating high quality with the Chinese zodiac culture. The Group also unveiled two new product series, namely "Sweet Heart" and "Pleasant Color", for the entry-level product segment. The product series are targeted at young consumers and will open a new chapter as part of the Group's product rejuvenation strategy.

The Group also sold foreign branded wines during the year. Imported mainly from France, Italy, Australia, Chile and the United States, the wines enter the Chinese market through the Group's existing distribution network. Having streamlined its portfolio, the Group currently sells about 50 imported grape wine products under approximately 10 brands.

During the year, the Group strengthened cooperation with distributors to operate online stores on such e-commerce platforms as JD.com, Tmall and Pinduoduo. Moreover, innovations were achieved across its brands and product categories, as well as business systems, procedures and models via new retail platforms including Weibo, RED (Xiaohongshu app), Kuai (Kuaishou app) and TikTok (Douyin app). The Group also established an e-commerce team and actively cultivated e-commerce live broadcasting talent to further expand its sales channels and build up a new customer base.

In October 2021, Dynasty held a grand opening ceremony in the new premises of its National-level Technology Center. The work station in the Center has commenced research for the first time on the selection of distinctive muscat yeast in order to create more mellow and enjoyable wines. Also, Dynasty Technology Center established a winemaking and wine tasting studio during the year.

In 2021, Dynasty continued to implement its market demand-oriented "5+4+N" product strategy, and completed the enhancement of the Group's organization structure. In the Group's strategy, "5" represents the five key series of products, comprising air dry series, seven-year reserve series, merlot series, classic series and best-selling series, and represents the goal of having full coverage of all mainstream price segments; "4" refers to the four advantageous categories, i.e. dry red wines, dry white wines, brandy and sparkling wines, and the aim of increasing the Group's vertical market share; and "N" stands for the development of "N" kinds of customized products to meet the diversified needs of Chinese consumers. In 2021, the Group achieved remarkable results from the adjustment of its products, sales channels and marketing campaigns.

With respect to its large-scale marketing campaign, the Group forged ahead with various endeavors, including showcasing products in 20,000 shops, hosting 1,000 wine tasting events and organizing 100 plant visits, so as to continue developing its point-of-sale network.

In the coming three years, the Group will strive to deploy 100,000 points of sale, add 1,000 distributors, and vigorously develop new channels via retail platforms. This will enable the Group to seize opportunities from the growing consumption market driven by young adults, and achieve the annual sales target of over RMB1 billion.

Mr. Wan Shoupeng, Chairman of Dynasty, said, "The Group is pleased that the "5+4+N" strategy has been effective in boosting product sales in 2021, which in turn has facilitated overall revenue growth. In the future, the Group will increase its investment in brand development in order to fully vitalize its brands as well as drive development of its major products. The latter will involve steadily enhancing quality and controlling prices to boost sales volume, with the aim of bringing Dynasty's superior wines to more consumers in China. Furthermore, in line with the industry development trend, Dynasty will strengthen its presence in the mass-market and mid-range product segments as well as target young consumers. In spite of the possible impact brought by sporadic COVID-19 cases in China, the Group is confident that its annual revenue will maintain a steady growth trend in 2022."


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comDynasty Fine Wines Group Limited ("Dynasty" or "the Group") (Stock Code: 828), a premier grape winemaker in China, today announced its audited annual results for the year ended 31 December 2021. Revenue in 2021 increased by 28% year-on-year to HK$306 million.

Bitcoin (BTC) Price Prediction: BTC/USD Retests the $45K Overhead Resistance, Can Bulls Breach the Recent High?

Bitcoin Battles the $45K Overhead Resistance, Can Bulls Breach the Recent High? – March 25, 2022 Today, BTC/USD has risen to retest the $45,400 overhead [...]

Week Ahead – An encouraging recovery

Are investors correct to be optimistic? Investors appear remarkably calm at the moment given the level of uncertainty we’re facing this year, from inflation to interest rates and even Covid, when you consider China is still embracing lockdowns. Throw soaring commodity prices into the mix and there’s plenty of reason to be pessimistic. But when […]

ZhongAn Online Released 2021 Annual Report

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

HONG KONG, Mar 25, 2022 - (ACN Newswire) - ZhongAn Online P & C Insurance Co. Ltd. ("ZhongAn Online" or "ZhongAn" or the "Company", HKEx: 6060) released its audited annual report for the year ended December 31, 2021 ("the reporting period"). The Company leveraged its strengths in insurance technology and rich resources connected through its ecosystems to further promote insurance inclusion. The Company provided insurance services for more than 500 million users with a caring hand, the number of customers receiving claim payment reached 129 million in 2021.

Adhering to the strategy of "sustainable growth with quality" and technology-driven cost reduction and efficiency improvement, the Company printed solid numbers in 2021. Gross written premium (GWP) reached RMB20.37 billion, representing a year-on-year increase of 21.9%. Combined ratio improved to 99.6%, marked the first underwriting profitable fiscal year in its history. Net profit attributable to owners of the parent reached RMB1.16 billion, representing a year-on-year increase of 110.3%, on the back of increased operational efficiency and robust growth of investment income.

Under the dual-engine growth strategy of "Insurance + Technology", ZhongAn exported its insurance technology capability and advanced Insuretech know-how to insurers and brokers, to fuel the digitalization in the insurance industry worldwide. During the reporting period, ZhongAn's technology export revenue reached RMB520 million, representing a year-on-year increase of 42%, and served 109 customers in the insurance industry.

Insurance segment - health ecosystem and digital lifestyle ecosystem remain top contributors with favorable channel mix shift

The health ecosystem recorded RMB7.69 billion in GWP, representing a year-on-year increase of 16%. The Company provided health protection to approximately 25.86 million insured customers in 2021, the number of paying users of individual health insurance reached 18 million, representing a year-on-year increase of 30%.

To achieve such performance, ZhongAn upheld to its philosophy of health inclusion. ZhongAn upgraded its flagship product, Personal Clinic Policy series, incorporating over 30 special rare disease drugs for the youth and launched exclusive medical protection plans for different customer groups such as chronic patients, women and the elderly. The latest version of Personal Clinic Policy also came with more value-added services including cancer screening, Internet hospital, traditional Chinese Medicine and so on.

The Company is committed to provide one-stop "insurance coverage + medical services" experience for users by expanding products and services from required medical scenarios such as in-patient and critical illness, to cover the daily needs of outpatient and emergency, critical illness follow-up treatment, chronic disease treatment, rehabilitation management, optional surgery and other scenarios.

The digital lifestyle ecosystem recorded GWP of RMB7.29 billion in 2021, representing a year-on-year increase of 16%. As new consumption scenarios evolved, ZhongAn actively explore and launch innovative products by leveraging its resources of over 300 strategic ecosystem partners and its cutting-edge technology to solve customers' pain-points in their daily digital life.

Riding the wave of e-commerce 2.0, ZhongAn launched a new version of shipping return policy customized for livestreaming e-commerce platforms such as TikTok and Kuai, and the premium contributed by livestreaming e-commerce channels accounted for more than 20% of the overall shipping return policy in 2021.

Meanwhile, the innovative products featured by pet insurance and phone screen cracking insurance also saw strong growth in 2021. Relying on the layout of pet O2O ecosystem, the annualized premium of pet insurance has exceeded RMB100 million, representing a year-on-year increase of over 250% and its market share was among the top in mainland China. Powered by its optical character recognition, the Company's phone screen cracking insurance grew by over 65% and remained the top-tier insurers for such product.

Among total GWP from digital lifestyle ecosystem, the premium income from innovative business represented by pet insurance, phone screen cracking insurance and Personal Accident Policy accounted for 19% in 2021, representing a year-on-year increase of 29%.

Moreover, in 2021 ZhongAn continued to build its brand and proprietary channels. In 2021, the premium from proprietary channels amounted to RMB3.6 billion, representing a year-on-year increase of 66.4%. The Company was pleasant to see such favorable channel mix shift, with proprietary channel contributing over 18% of GWP in 2021. The per capita premium contribution of proprietary channels reached RMB506, representing a year-on-year increase of 20% thanks to robust renewal rate and cross-selling efforts in proprietary channels.

Technology segment - facilitating the digital transformation of the global insurance industry

As a leading insurance technology company, ZhongAn continued to explore cutting-edge technology fields such as artificial intelligence, blockchain, cloud computing, big data and life sciences technology, and utilized technology to reshape the entire insurance value chain. Last year, the Company's R&D investment reached RMB1.13 billion, representing a year-on-year increase of 24.5%, accounting for 5.5% of the total GWP. There were 1,836 engineers and technicians, accounting for 48% of all employees.

ZhongAn promoted refined operation with Insurtech, enhancing user experience constantly. The cloud-based distributed core system "Wujieshan" helped ZhongAn to issue 7.7 billion insurance policies in 2021, and the number of customers receiving claim payment for the year reached 129 million. Enabled by its technology, the online claim settlement rate exceeds 95%.

At the same time, ZhongAn also helped insurers worldwide with their digital transformation by exporting modular Insuretech products. In 2021, the technology export revenue reached RMB520 million , representing a year-on-year increase of 42%, with the proportion of recurring revenue reaching 48%. ZhongAn served 109 customers in the insurance industry last year, a year-on-year increase of 34 new accounts.

In terms of overseas development, ZhongAn Technology has further expanded its business territory to Japan, Singapore, Malaysia, Indonesia to Vietnam, Thailand, Philippines and Europe, by working with insurance companies like AIA, Muang Thai Life, and PFI Mega Life.

ZA Bank, a pioneering advocate of virtual banking in Hong Kong with a one-stop digital financial service platform also made pleasant progress in 2021. Within two years, the number of customers exceeded 500,000, the deposit balance as of Dec 2021 reached HK$7 billion, and the loan balance quadrupled year-on-year to HK$2.5 billion.

In the future, ZhongAn will continue to focus on the needs of users, leverage technological strength to drive innovation, build and improve the ZhongAn brand in the eyes of users, constantly practice insurance inclusion and create long-term value.

About ZhongAn Online P&C Insurance Co Ltd (Stock Code:6060.HK)

ZhongAn Online P&C Insurance Co., Ltd. is a leading online-only InsureTech company in China. Founded in October 2013, the Company adopts an ecosystem-oriented approach and focuses on customers' lives on the Internet, meeting customers' diversified protection needs and creating value for them through ecosystem partners and its proprietary platform. ZhongAn Online seamlessly integrates technology across its insurance business, and now exports its technology to help other companies accelerate their growth. On 28 September 2017, ZhongAn Online became the first Fintech company listed on the HKEx (Ticker: 6060) and since 2018, the Company started expanding its Fintech and InsureTech solutions to various international markets.

For further information, please contact:

ZhongAn Online IR Team

Email: ir@zhongan.com


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comZhongAn Online P & C Insurance Co. Ltd. ("ZhongAn Online" or "ZhongAn" or the "Company", HKEx: 6060) released its audited annual report for the year ended December 31, 2021 ("the reporting period").

Angelalign Announces 2021 Annual Results

HONG KONG, Mar 25, 2022 - (ACN Newswire) - Angelalign Technology Inc. ("Angelalign" or "Company"; stock code 6699) was pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2021 (the "Reporting Period") today.

In 2021, the company achieved robust business growth amid the market volatility and challenge. The company recognized total revenue of RMB1,271.7 million, representing a year-over-year growth of 55.7%, of which 93.1%, 5.3% and 1.6% were generated from provision of clear aligner treatment solutions, sales of intraoral scanner and provision of other services, respectively. It is gratifying to note that revenue generated from its core business, namely the clear aligner treatment solutions, achieved a year-over-year growth of 48.2%, despite the impact of external headwinds. In addition, leveraging its refined operational management capabilities, the company delivered steady earnings growth, with the adjusted EBITDA increasing by 40.7% year-over-year to RMB417.5 million, and the adjusted net profit increasing by 52.9% year-over-year to RMB347.5 million.

Continuously penetrate into the digital orthodontics market and strengthen its diversified product portfolio

With a profound understanding of the medical principles and practices of digital orthodontics and insight into the needs of various dental professionals and patients in China, the company have built a diversified product portfolio and currently market four lines of clear aligners with a variety of unique features that appeal to different user segments, including Angelalign that targets the mass market, Angelalign Pro that targets the high-end market, Angelalign Kid that focuses on early intervention for children, and COMFOS as a good value-for-money product.

During the Reporting Period, the company had 183,200 case shipments, representing a year over-year increase of 33.1%. Specifically, the case shipments of Angelalign , Angelalign Pro , Angelalign Kid and COMFOS achieved a year-over-year growth rate of 10.4%, 52.5%, 116.0% and 56.2%, respectively.

Optimize the digital treatment experience and achieve all-round empowerment with medical-centric and intelligent technological services

To optimize the digital treatment experience, the company expanded its business into sales of intraoral scanners in 2021, which allows dental professionals to significantly improve their communication efficiency with prospective patients. Leveraging the compatibility of Make It with major intraoral scanners, which is a built-in case assessment support module of iOrtho, its cloud-based service platform, dental professionals can present to a prospective patient an image of his or her own current dentition next to the simulated post-treatment position through a dual view layout within a few minutes of intraoral scanning.

The company believes that large-scale, systematic, and continuous professional training in clear aligner treatment helps develop dental professionals' recognition of, and confidence in, Angelalign's services. In 2021, the company continued to empower more Chinese dental professionals with varying levels of sophistication by further optimizing its training content and curriculum around the treatment process and core issues in clinical practice. During the Reporting Period, the company served approximately 25,000 dental professionals, representing a year-over-year increase of 25.6%.

Integrate interdisciplinary capabilities in five major areas and continuously invest in R&D initiatives to make continuous breakthroughs in product and technology development

Benefiting from its long-term investment of R&D resources, the company has established strong interdisciplinary R&D capabilities in five major areas, including clinical stomatology, biomechanics, materials science, computer science and intelligent manufacturing technologies. Based on these interdisciplinary R&D capabilities, the company has developed reliable technology and data platforms, including masterForce , masterControl and artificial intelligence multimodal biological data platform ME . In 2021, the company achieved a series of innovative results in materials, technologies, software and equipment, which focus on product performance, clinical convenience, optimization of treatment planning and differentiation of products and technical services.

The company has formulated the industry standard of "Dentistry - Orthodontics Appliance Diaphragm" in collaboration with Peking University Hospital of Stomatology. The company also obtained the approval by the National Standardization Technical Committee for Oral Materials and Instruments (SAC/TC99) of another industry standard project of "Dentistry - Bracket-free Diaphragmtype Orthodontic Appliance" in 2021. During the Reporting Period, the company incurred R&D expenses of RMB123.1 million, accounting for 9.7% of its revenue. As of December 31, 2021, the company had registered 117 patents, and 16 software copyrights.

The company has established good cooperation with many renowned stomatology schools and universities in China. The company has proactively conducted industry-academia research cooperation and prioritized the application of scientific research results and other industrialization achievements. Over the recent years, the company has set up special research funds for orthodontics with the Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Peking University Hospital of Stomatology, Sichuan University Huaxi Stomatology Hospital and Wuhan University Stomatological Hospital, respectively, to carry out joint R&D initiatives. The company also conducted research on orthodontic materials with the State Key Laboratory of Molecular Engineering of Polymers of Fudan University, the preliminary research results of which has been accepted by Regenerative Biomaterials, an SCI journal published by the Oxford University Press

Continue to enhance brand awareness and academic influence

As a leader in driving the development of China's clear aligner treatment industry, "Angelalign" has become the best known and the most trustworthy domestic brand among China's clear aligner treatment solution providers. In 2021, the company continued to enhance brand awareness and academic influence of "Angelalign" through industry-academia research collaboration, academic sharing, promoting campaigns for popular science and charitable campaigns.

The company has been appointed as a sponsor by the Bureau of Training of General Administration of Sport of China to provide clear aligner treatment for national athletes since 2017, with its clear aligners being designated as the Approved Products for National Team Athletes. In the Beijing 2022 Winter Olympic Games and the 2022 AFC Women's Asian Cup, a number of Chinese athletes who won gold medals smiled with "Angelalign" clear aligners.

Optimize scalable and intelligent mass customization capability to achieve lean manufacturing

The company believes that its accumulated intelligent manufacturing capabilities, a "mass customization" model and scalable manufacturing capabilities are the solid foundation for its long-term business growth.

The company's Angelalign Chuangmei Center in Wuxi City comprises new manufacturing facilities and a research and development center with a gross floor area of approximately 126,000 square meters. During the Reporting Period, the first phase of its Angelalign Chuangmei Center was completed. The company also completed the commissioning process of one established automated production line in the first quarter of 2022, which will be put into use based on demands of its products. In addition, the company applied intelligent and innovative technologies to upgrade the information systems, technics and equipment of its existing automated production lines, and has enabled a fully automated outer packaging system to enhance the automation of the product outer packaging process, which significantly improves the production efficiency.

Looking forward, the company aims to serve dental professionals and their patients with more customized products and services, refined manufacturing capability and flexible supply chain. To this end, the company intends to pursue the following key strategies to grow its business sustainably and maintain its market leadership: (1) strengthen R&D capabilities and continue orthodontic solution innovations; (2) further intelligentize and digitalize its systems to improve operational efficiency; (3) optimize medical services to enhance user experience; (4) increase production capacity and improve production efficiency; (5) solidify its market leading position by expanding sales network and enhancing brand awareness and academic influence. The Company will continue leveraging its market leadership and its intimate understanding of China's digital orthodontics market, the company believes that it is well positioned to capture the upside potential of the enormous market. In the future, the Group will continue to deepen its main business, conduct solid and steady operations, and strive to enhance the company's performance and market value, and strive to create more investment returns for shareholders.

About Angelalign Technology Inc.
Angelalign Technology Inc. is a leading clear aligner treatment solution provider in China. The Company facilitates dental professionals throughout the entire clear aligner treatment process with Angelalign clear aligner system, which comprises a trio of interrelated components: (1) digitally-assisted case assessment support and treatment planning services, (2) customized, removable clear aligners based on specific treatment plans, and (3) iOrtho, a cloud-based service platform. Established in 2003, Angelalign has always been committed to helping dentists diagnose and treat in a steady, easy, quick and accurate way through digital technology-driven products and technical services to smile confidently with the help of technology.


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAngelalign Technology Inc. ("Angelalign" or "Company"; stock code 6699) was pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2021 (the "Reporting Period") today.
Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Angelalign Announces 2021 Annual Results

HONG KONG, Mar 25, 2022 - (ACN Newswire) - Angelalign Technology Inc. ("Angelalign" or "Company"; stock code 6699) was pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2021 (the "Reporting Period") today.

In 2021, the company achieved robust business growth amid the market volatility and challenge. The company recognized total revenue of RMB1,271.7 million, representing a year-over-year growth of 55.7%, of which 93.1%, 5.3% and 1.6% were generated from provision of clear aligner treatment solutions, sales of intraoral scanner and provision of other services, respectively. It is gratifying to note that revenue generated from its core business, namely the clear aligner treatment solutions, achieved a year-over-year growth of 48.2%, despite the impact of external headwinds. In addition, leveraging its refined operational management capabilities, the company delivered steady earnings growth, with the adjusted EBITDA increasing by 40.7% year-over-year to RMB417.5 million, and the adjusted net profit increasing by 52.9% year-over-year to RMB347.5 million.

Continuously penetrate into the digital orthodontics market and strengthen its diversified product portfolio

With a profound understanding of the medical principles and practices of digital orthodontics and insight into the needs of various dental professionals and patients in China, the company have built a diversified product portfolio and currently market four lines of clear aligners with a variety of unique features that appeal to different user segments, including Angelalign that targets the mass market, Angelalign Pro that targets the high-end market, Angelalign Kid that focuses on early intervention for children, and COMFOS as a good value-for-money product.

During the Reporting Period, the company had 183,200 case shipments, representing a year over-year increase of 33.1%. Specifically, the case shipments of Angelalign , Angelalign Pro , Angelalign Kid and COMFOS achieved a year-over-year growth rate of 10.4%, 52.5%, 116.0% and 56.2%, respectively.

Optimize the digital treatment experience and achieve all-round empowerment with medical-centric and intelligent technological services

To optimize the digital treatment experience, the company expanded its business into sales of intraoral scanners in 2021, which allows dental professionals to significantly improve their communication efficiency with prospective patients. Leveraging the compatibility of Make It with major intraoral scanners, which is a built-in case assessment support module of iOrtho, its cloud-based service platform, dental professionals can present to a prospective patient an image of his or her own current dentition next to the simulated post-treatment position through a dual view layout within a few minutes of intraoral scanning.

The company believes that large-scale, systematic, and continuous professional training in clear aligner treatment helps develop dental professionals' recognition of, and confidence in, Angelalign's services. In 2021, the company continued to empower more Chinese dental professionals with varying levels of sophistication by further optimizing its training content and curriculum around the treatment process and core issues in clinical practice. During the Reporting Period, the company served approximately 25,000 dental professionals, representing a year-over-year increase of 25.6%.

Integrate interdisciplinary capabilities in five major areas and continuously invest in R&D initiatives to make continuous breakthroughs in product and technology development

Benefiting from its long-term investment of R&D resources, the company has established strong interdisciplinary R&D capabilities in five major areas, including clinical stomatology, biomechanics, materials science, computer science and intelligent manufacturing technologies. Based on these interdisciplinary R&D capabilities, the company has developed reliable technology and data platforms, including masterForce , masterControl and artificial intelligence multimodal biological data platform ME . In 2021, the company achieved a series of innovative results in materials, technologies, software and equipment, which focus on product performance, clinical convenience, optimization of treatment planning and differentiation of products and technical services.

The company has formulated the industry standard of "Dentistry - Orthodontics Appliance Diaphragm" in collaboration with Peking University Hospital of Stomatology. The company also obtained the approval by the National Standardization Technical Committee for Oral Materials and Instruments (SAC/TC99) of another industry standard project of "Dentistry - Bracket-free Diaphragmtype Orthodontic Appliance" in 2021. During the Reporting Period, the company incurred R&D expenses of RMB123.1 million, accounting for 9.7% of its revenue. As of December 31, 2021, the company had registered 117 patents, and 16 software copyrights.

The company has established good cooperation with many renowned stomatology schools and universities in China. The company has proactively conducted industry-academia research cooperation and prioritized the application of scientific research results and other industrialization achievements. Over the recent years, the company has set up special research funds for orthodontics with the Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Peking University Hospital of Stomatology, Sichuan University Huaxi Stomatology Hospital and Wuhan University Stomatological Hospital, respectively, to carry out joint R&D initiatives. The company also conducted research on orthodontic materials with the State Key Laboratory of Molecular Engineering of Polymers of Fudan University, the preliminary research results of which has been accepted by Regenerative Biomaterials, an SCI journal published by the Oxford University Press

Continue to enhance brand awareness and academic influence

As a leader in driving the development of China's clear aligner treatment industry, "Angelalign" has become the best known and the most trustworthy domestic brand among China's clear aligner treatment solution providers. In 2021, the company continued to enhance brand awareness and academic influence of "Angelalign" through industry-academia research collaboration, academic sharing, promoting campaigns for popular science and charitable campaigns.

The company has been appointed as a sponsor by the Bureau of Training of General Administration of Sport of China to provide clear aligner treatment for national athletes since 2017, with its clear aligners being designated as the Approved Products for National Team Athletes. In the Beijing 2022 Winter Olympic Games and the 2022 AFC Women's Asian Cup, a number of Chinese athletes who won gold medals smiled with "Angelalign" clear aligners.

Optimize scalable and intelligent mass customization capability to achieve lean manufacturing

The company believes that its accumulated intelligent manufacturing capabilities, a "mass customization" model and scalable manufacturing capabilities are the solid foundation for its long-term business growth.

The company's Angelalign Chuangmei Center in Wuxi City comprises new manufacturing facilities and a research and development center with a gross floor area of approximately 126,000 square meters. During the Reporting Period, the first phase of its Angelalign Chuangmei Center was completed. The company also completed the commissioning process of one established automated production line in the first quarter of 2022, which will be put into use based on demands of its products. In addition, the company applied intelligent and innovative technologies to upgrade the information systems, technics and equipment of its existing automated production lines, and has enabled a fully automated outer packaging system to enhance the automation of the product outer packaging process, which significantly improves the production efficiency.

Looking forward, the company aims to serve dental professionals and their patients with more customized products and services, refined manufacturing capability and flexible supply chain. To this end, the company intends to pursue the following key strategies to grow its business sustainably and maintain its market leadership: (1) strengthen R&D capabilities and continue orthodontic solution innovations; (2) further intelligentize and digitalize its systems to improve operational efficiency; (3) optimize medical services to enhance user experience; (4) increase production capacity and improve production efficiency; (5) solidify its market leading position by expanding sales network and enhancing brand awareness and academic influence. The Company will continue leveraging its market leadership and its intimate understanding of China's digital orthodontics market, the company believes that it is well positioned to capture the upside potential of the enormous market. In the future, the Group will continue to deepen its main business, conduct solid and steady operations, and strive to enhance the company's performance and market value, and strive to create more investment returns for shareholders.

About Angelalign Technology Inc.
Angelalign Technology Inc. is a leading clear aligner treatment solution provider in China. The Company facilitates dental professionals throughout the entire clear aligner treatment process with Angelalign clear aligner system, which comprises a trio of interrelated components: (1) digitally-assisted case assessment support and treatment planning services, (2) customized, removable clear aligners based on specific treatment plans, and (3) iOrtho, a cloud-based service platform. Established in 2003, Angelalign has always been committed to helping dentists diagnose and treat in a steady, easy, quick and accurate way through digital technology-driven products and technical services to smile confidently with the help of technology.


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAngelalign Technology Inc. ("Angelalign" or "Company"; stock code 6699) was pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2021 (the "Reporting Period") today.

Angelalign Announces 2021 Annual Results

HONG KONG, Mar 25, 2022 - (ACN Newswire) - Angelalign Technology Inc. ("Angelalign" or "Company"; stock code 6699) was pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2021 (the "Reporting Period") today.

In 2021, the company achieved robust business growth amid the market volatility and challenge. The company recognized total revenue of RMB1,271.7 million, representing a year-over-year growth of 55.7%, of which 93.1%, 5.3% and 1.6% were generated from provision of clear aligner treatment solutions, sales of intraoral scanner and provision of other services, respectively. It is gratifying to note that revenue generated from its core business, namely the clear aligner treatment solutions, achieved a year-over-year growth of 48.2%, despite the impact of external headwinds. In addition, leveraging its refined operational management capabilities, the company delivered steady earnings growth, with the adjusted EBITDA increasing by 40.7% year-over-year to RMB417.5 million, and the adjusted net profit increasing by 52.9% year-over-year to RMB347.5 million.

Continuously penetrate into the digital orthodontics market and strengthen its diversified product portfolio

With a profound understanding of the medical principles and practices of digital orthodontics and insight into the needs of various dental professionals and patients in China, the company have built a diversified product portfolio and currently market four lines of clear aligners with a variety of unique features that appeal to different user segments, including Angelalign that targets the mass market, Angelalign Pro that targets the high-end market, Angelalign Kid that focuses on early intervention for children, and COMFOS as a good value-for-money product.

During the Reporting Period, the company had 183,200 case shipments, representing a year over-year increase of 33.1%. Specifically, the case shipments of Angelalign , Angelalign Pro , Angelalign Kid and COMFOS achieved a year-over-year growth rate of 10.4%, 52.5%, 116.0% and 56.2%, respectively.

Optimize the digital treatment experience and achieve all-round empowerment with medical-centric and intelligent technological services

To optimize the digital treatment experience, the company expanded its business into sales of intraoral scanners in 2021, which allows dental professionals to significantly improve their communication efficiency with prospective patients. Leveraging the compatibility of Make It with major intraoral scanners, which is a built-in case assessment support module of iOrtho, its cloud-based service platform, dental professionals can present to a prospective patient an image of his or her own current dentition next to the simulated post-treatment position through a dual view layout within a few minutes of intraoral scanning.

The company believes that large-scale, systematic, and continuous professional training in clear aligner treatment helps develop dental professionals' recognition of, and confidence in, Angelalign's services. In 2021, the company continued to empower more Chinese dental professionals with varying levels of sophistication by further optimizing its training content and curriculum around the treatment process and core issues in clinical practice. During the Reporting Period, the company served approximately 25,000 dental professionals, representing a year-over-year increase of 25.6%.

Integrate interdisciplinary capabilities in five major areas and continuously invest in R&D initiatives to make continuous breakthroughs in product and technology development

Benefiting from its long-term investment of R&D resources, the company has established strong interdisciplinary R&D capabilities in five major areas, including clinical stomatology, biomechanics, materials science, computer science and intelligent manufacturing technologies. Based on these interdisciplinary R&D capabilities, the company has developed reliable technology and data platforms, including masterForce , masterControl and artificial intelligence multimodal biological data platform ME . In 2021, the company achieved a series of innovative results in materials, technologies, software and equipment, which focus on product performance, clinical convenience, optimization of treatment planning and differentiation of products and technical services.

The company has formulated the industry standard of "Dentistry - Orthodontics Appliance Diaphragm" in collaboration with Peking University Hospital of Stomatology. The company also obtained the approval by the National Standardization Technical Committee for Oral Materials and Instruments (SAC/TC99) of another industry standard project of "Dentistry - Bracket-free Diaphragmtype Orthodontic Appliance" in 2021. During the Reporting Period, the company incurred R&D expenses of RMB123.1 million, accounting for 9.7% of its revenue. As of December 31, 2021, the company had registered 117 patents, and 16 software copyrights.

The company has established good cooperation with many renowned stomatology schools and universities in China. The company has proactively conducted industry-academia research cooperation and prioritized the application of scientific research results and other industrialization achievements. Over the recent years, the company has set up special research funds for orthodontics with the Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Peking University Hospital of Stomatology, Sichuan University Huaxi Stomatology Hospital and Wuhan University Stomatological Hospital, respectively, to carry out joint R&D initiatives. The company also conducted research on orthodontic materials with the State Key Laboratory of Molecular Engineering of Polymers of Fudan University, the preliminary research results of which has been accepted by Regenerative Biomaterials, an SCI journal published by the Oxford University Press

Continue to enhance brand awareness and academic influence

As a leader in driving the development of China's clear aligner treatment industry, "Angelalign" has become the best known and the most trustworthy domestic brand among China's clear aligner treatment solution providers. In 2021, the company continued to enhance brand awareness and academic influence of "Angelalign" through industry-academia research collaboration, academic sharing, promoting campaigns for popular science and charitable campaigns.

The company has been appointed as a sponsor by the Bureau of Training of General Administration of Sport of China to provide clear aligner treatment for national athletes since 2017, with its clear aligners being designated as the Approved Products for National Team Athletes. In the Beijing 2022 Winter Olympic Games and the 2022 AFC Women's Asian Cup, a number of Chinese athletes who won gold medals smiled with "Angelalign" clear aligners.

Optimize scalable and intelligent mass customization capability to achieve lean manufacturing

The company believes that its accumulated intelligent manufacturing capabilities, a "mass customization" model and scalable manufacturing capabilities are the solid foundation for its long-term business growth.

The company's Angelalign Chuangmei Center in Wuxi City comprises new manufacturing facilities and a research and development center with a gross floor area of approximately 126,000 square meters. During the Reporting Period, the first phase of its Angelalign Chuangmei Center was completed. The company also completed the commissioning process of one established automated production line in the first quarter of 2022, which will be put into use based on demands of its products. In addition, the company applied intelligent and innovative technologies to upgrade the information systems, technics and equipment of its existing automated production lines, and has enabled a fully automated outer packaging system to enhance the automation of the product outer packaging process, which significantly improves the production efficiency.

Looking forward, the company aims to serve dental professionals and their patients with more customized products and services, refined manufacturing capability and flexible supply chain. To this end, the company intends to pursue the following key strategies to grow its business sustainably and maintain its market leadership: (1) strengthen R&D capabilities and continue orthodontic solution innovations; (2) further intelligentize and digitalize its systems to improve operational efficiency; (3) optimize medical services to enhance user experience; (4) increase production capacity and improve production efficiency; (5) solidify its market leading position by expanding sales network and enhancing brand awareness and academic influence. The Company will continue leveraging its market leadership and its intimate understanding of China's digital orthodontics market, the company believes that it is well positioned to capture the upside potential of the enormous market. In the future, the Group will continue to deepen its main business, conduct solid and steady operations, and strive to enhance the company's performance and market value, and strive to create more investment returns for shareholders.

About Angelalign Technology Inc.
Angelalign Technology Inc. is a leading clear aligner treatment solution provider in China. The Company facilitates dental professionals throughout the entire clear aligner treatment process with Angelalign clear aligner system, which comprises a trio of interrelated components: (1) digitally-assisted case assessment support and treatment planning services, (2) customized, removable clear aligners based on specific treatment plans, and (3) iOrtho, a cloud-based service platform. Established in 2003, Angelalign has always been committed to helping dentists diagnose and treat in a steady, easy, quick and accurate way through digital technology-driven products and technical services to smile confidently with the help of technology.


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAngelalign Technology Inc. ("Angelalign" or "Company"; stock code 6699) was pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2021 (the "Reporting Period") today.

China takes aim at corruption in underground Bitcoin mines

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption China’s anti-graft watchdog has warned that authorities are keeping a close eye on possible corruption behind underground cryptocurrency mining that persists even after the government banned the sector.  See related article: China ousts former official for supporting crypto mining, corruption Fast facts The Central Commission for Discipline Inspection (CCDI) of the Chinese Communist Party said […]

Selling gas and oil for Bitcoins? This Russian lawmaker thinks so

Pavel Zavalny, the head of Russia’s Committee on Energy, said earlier today that the country will enable friendly countries to pay for oil, gas, and other exports in Bitcoin.

The post Selling gas and oil for Bitcoins? This Russian lawmaker thinks so appeared first on CryptoSlate.

Just-In: Russia Could Be Willing To Accept Bitcoin Payments For Its Natural Gas

The fears of regulators around the world about Russia using Bitcoin to evade sanctions could be about to come true as a top Russian government executive has revealed that the country’s authorities could be willing to accept Bitcoin payments for its natural gas. Duma committee deputy Pavel Zavalny revealed this development on Thursday during a

The post Just-In: Russia Could Be Willing To Accept Bitcoin Payments For Its Natural Gas appeared first on CoinGape.

Cato Institute slams Sen. Warren’s sanctions evasion bill: “collateral damage”

Last week United States Senator Elizabeth Warren (D-MA), along with ten other democrat senators, introduced a bill to block cryptocurrency companies from conducting business with sanctioned companies, fearing cryptocurrencies might constitute a vehicle for evading sanctions against Russia in the ongoing war with Ukraine.

The post Cato Institute slams Sen. Warren’s sanctions evasion bill: “collateral damage” appeared first on CryptoSlate.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Recent articles

spot_img